Reduction of UV-A radiation induced by calcipotriol in the treatment of vulgar psoriasis with oral psoralen plus UV-A

Kokelj, F; Plozzer, Carmela; Torsello, Pierpaolo

doi:10.1001/archderm.133.5.668

Cited by 10 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two recent trials 24,25 addressing the combined use of topical calcipotriene and UV-B phototherapy were excluded because they reported on nonrelevant outcomes for this study. A further 5 trials [26][27][28][29][30] were excluded because of lack of randomization. Similar qualitative results were obtained in these trials, which gave us some confidence about the robustness of our conclusions.…”

Section: Limitations Of Studymentioning

confidence: 99%

Combination Regimens of Topical Calcipotriene in Chronic Plaque Psoriasis

Ashcroft

Po²,

Williams³

et al. 2000

Arch Dermatol

View full text Add to dashboard Cite

To examine the efficacy and tolerability of calcipotriene combined with phototherapy or systemic therapies compared with monotherapy for the treatment of chronic plaque psoriasis.Design: Quantitative systematic review of 11 randomized controlled trials involving a total of 756 patients with plaque psoriasis.Main Outcome Measures: Rate ratios (RRs) for marked improvement or clearance in patient and investigator overall assessments of response; mean difference in percentage change in Psoriasis Area and Severity Index; and RRs for clearance in patient and investigator overall assessments of response. Adverse effects were estimated with the RR and the rate difference in terms of withdrawal rate, proportion of patients experiencing adverse events, and proportion of patients with cutaneous and noncutaneous adverse effects.Results: Antipsoriatic effects of acitretin, cyclosporine, and psoralen-UV-A phototherapy were enhanced with the addition of topical calcipotriene using the Psoriasis Area and Severity Index as the outcome, but this is not translated into an increase in the number of patients who achieve at least marked improvement. At the end of treatment, the RRs for marked improvement or clearance in patient assessments were as follows: calcipotriene plus acitretin vs acitretin alone (12 weeks), 1.4 (95% confidence interval [CI], 1.0-1.9); calcipotriene plus cyclo-

show abstract